寡聚对苯乙炔与多肽拮抗剂RM26的偶联及131I标记研究

doi:10.7538/tws.2016.29.03.0158

同位素 ›› 2016, Vol. 29 ›› Issue (3): 158-163.DOI: 10.7538/tws.2016.29.03.0158

• 放射性药物与标记化合物 • 上一篇下一篇

寡聚对苯乙炔与多肽拮抗剂RM26的偶联及¹³¹I标记研究

蹇源^1,2;周志军²;卓连刚²;赵鹏²;廖伟²;王关全²;刘宁¹

1.四川大学原子核科学技术研究所辐射物理及技术教育部国家重点实验室，四川成都610064；2.中国工程物理研究院，四川绵阳621900

出版日期:2016-08-20 发布日期:2016-08-10

Coupling Reaction of Oligo p-Phenylene Ethynylene and Peptide Antagonist RM26 Labeling with ¹³¹I

JIAN Yuan^1,2;ZHOU Zhi-jun²;ZHUO Lian-gang²;ZHAO Peng²;LIAO Wei²;WANG Guan-quan²;LIU Ning¹

1.Institute of Nuclear Science and Technology, Key Laboratory of Radiation Physics and Technology (Sichuan University), Ministry of Education, Sichuan University, Chengdu 610064, China;2.Institute of Nuclear Physics and Chemistry, China Academy of Engineering Physics, Mianyang 621900, China

Online:2016-08-20 Published:2016-08-10

摘要/Abstract

摘要：

结合寡聚对苯乙炔（oligo p-phenylene ethynylene, OPE）较强细胞膜穿透能力和多肽拮抗剂RM26对PC-3癌细胞的高亲和性，设计合成OPE-RM26偶联物。采用Iodogen涂管法对偶联物进行¹³¹I标记，得到标记率为95%的放射性标记物¹³¹I-OPE-RM26，室温下放置24 h后其放化纯度仍大于90%，具有良好的体外稳定性。研究结果为制备具有靶点识别、膜穿透性、射线杀伤的多功能放射性药物提供参考。

关键词: 寡聚对苯乙炔, 多肽拮抗剂, 偶联反应, ¹³¹I标记

Abstract:

Investigations reveale that oligo p-phenylene ethynylene (OPE) molecule can insert into cell membrane, which leads to its cellular internization capacility. Antagonists have high cancer cell affinity, high uptake in cancer cells and fast clearance in normal tissue, these capabilities have attracted much research interest in radiopharmaceutical development. Combining the strong cell-penetrating ability and high affinity of Gastrin-releasing peptide which is overexpressed in the PC-3 cells, the thesis designed and synthesized unsymmetric OPE(NH₂) molecule. Then the OPE(NH₂) molecule was followed by the coupling reaction with RM26 peptide to obtain the OPE-RM26, and (Tyr)₃-RM26 was also got for controling study. After that, the (Tyr)₃-RM26 and OPE-RM26 were radiolabeled with I-131 to give high radiolabeling yields that could up to 95%. The radiolabeling compound was stable after 24 h storage at room temperature. These labeled compounds are ready for animal in-vivo experiment. It is expected that OPE-RM26-¹³¹I has multi-properties with targeting membrane crossing fire of radioactive elements. The molecule may fast travel to the target tissue and bind to GRP receptor and internalized into cancer cells. The casade process will give rise to its cancer cell toxicity due to longer retention and more killing effect of ray’s irradiation to cancer cells. In this way, OPE-RM26-¹³¹I can achieve better anti-cancer ability.

Key words: oligo p-phenylene ethynylene, peptide antagonist, coupling reaction, I-131labeling

蹇源;周志军;卓连刚;赵鹏;廖伟;王关全;刘宁. 寡聚对苯乙炔与多肽拮抗剂RM26的偶联及¹³¹I标记研究[J]. 同位素, 2016, 29(3): 158-163.

JIAN Yuan;ZHOU Zhi-jun;ZHUO Lian-gang;ZHAO Peng;LIAO Wei;WANG Guan-quan;LIU Ning. Coupling Reaction of Oligo p-Phenylene Ethynylene and Peptide Antagonist RM26 Labeling with ¹³¹I[J]. Journal of Isotopes, 2016, 29(3): 158-163.

参考文献

［1］Lu L, Rininsland F H, Wittenburg S K, et al. Biocidal activity of a light-absorbing fluorescent conjugated polyelectrolyte［J］. Langmuir, 2005, 21: 10154-10159.
［2］Ogawa K, Chemburu S, Lopez G P, et al. Conjugated polyelectrolyte-grafted silica microspheres［J］. Langmuir, 2007, 23: 4541-4548.
［3］Corbitt T S, Sommer J R, Chemburu S, et al. Conjugated polyelectrolyte capsules: light-activated antimicrobial micro “Roach Motels”［J］. ACS Appl Mater Interface, 2009, 1: 48-52.
［4］Xing C F, Xu Q L, Tang H W, et al. Conjugated polymer/porphyrin complexes for efficient energy transfer and improving light-activated antibacterial activity［J］. J Am Chem Soc , 2009, 131: 13117-13124.
［5］Yuan H X, Chong H, Wang B, et al. Chemical molecule-induced light-activated system for anticancer and antifungal activities［J］. J Am Chem Soc , 2012, 134: 13184-13187.
［6］Zhou Z J, Corbitt T S, Parthasarathy A, et al. “End-Only” functionalized oligo (phenylene ethynylene)s: synthesis, photophysical and biocidal activity［J］. J Phys Chem Lett, 2010, 1: 3207-3212.
［7］Wang Y, Corbitt T S, Jett S D, et al. Direct visualization of bactericidal action of cationic conjugated polyelectrolytes and oligomers［J］. Langmuir, 2012, 28: 65-70.
［8］Niu Y, Chang T M, Yeh S, et al. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails［J］. Oncogene, 2010, 29(25): 3593-3604.
［9］Tosoian J S, Loeb P S A, Beyond. The Past, present and future of investigative biomarkers for prostate cancer［J］. The Scientific World Journal, 2010, 10: 1919-1931.
［10］Mohler J. Prostate cancer［J］. Journal of the National Comprehensive Cancer Network, 2010, 8(2): 162-200.
［11］Ginj M. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors［J］. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103(44): 16436-16441.
［12］Wiele C V D, Dumont F, Broecke R V, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study［J］. European Journal of Nuclear Medicine, 2000, 27(11): 1694-1699.
［13］Nock B . Tc-99m Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging［J］. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30(2): 247-258.
［14］Hoffman T J, Smith C J. True radiotracers: Cu-64 targeting vectors based upon bombesin peptide［J］. Nuclear Medicine and Biology, 2009,36(6): 579-585.
［15］Lantry L E. Lu-177-AMBA: Synthesis and characterization of a selective Lu-177-labeled GRP-R agonist for systemic radiotherapy of prostate cancer［J］. Journal of Nuclear Medicine, 2006, 47(7): 1144-1152.
［16］Maddalena M E . Lu-177-AMBA Biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression［J］. Journal of Nuclear Medicine, 2009, 50(12): 2017-2024.
［17］Cescato R. Bombesin receptor antagonists may be preferable to agonists for tumor targeting［J］. Journal of Nuclear Medcine, 2008, 49: 318-326.
［18］Mansi R, Fleischmann A, Mäcke H. Targeting GRPR in urological cancers-from basic research to clinical application［J］. Nature Reviews Urology, 2013, 10: 235-244.
［19］Kroll C, Mansi R, Braun F. Hybrid bombesin analogues: combining an agonist and an antagonist in defined distances for optimized tumor targeting［J］. J Am Chem Soc, 2013, 135(45): 16793-16796.

[1]	卢霞 ;王荣福 ;张春丽 . 新型多肽示踪剂¹³¹I-RRL肿瘤分子显像研究[J]. 同位素, 2011, 24(3): 177-181.
[2]	作者. ~(153)Sm 标记 DTPA-蛋白的研究 [J]. 同位素, 1998, 11 (4 ): 37-40 .

寡聚对苯乙炔与多肽拮抗剂RM26的偶联及¹³¹I标记研究

Coupling Reaction of Oligo p-Phenylene Ethynylene and Peptide Antagonist RM26 Labeling with ¹³¹I

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics